Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
RESEARCH TOOLSreports
EYPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.90 - $29.31
Previous CloseN/A
Volume354.62K
Average Volume (3M)865.67K
Market Cap
$446.36M
Enterprise Value$204.47M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Feb 27, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding68,251,030
10 Day Avg. Volume1,216,017
30 Day Avg. Volume865,670
Standard Deviation0.45
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.76
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$27.60Price Target Upside334.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
EyePoint Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Drug Efficacy And SafetyThe 24-week Phase 2 data for Duravyu in diabetic macular edema showed positive results, demonstrating an excellent safety profile and convincing efficacy, supporting its advancement into Phase 3.
Financial PositionEyepoint Pharma potentially only needs one Phase 3 trial for approval in diabetic macular edema and could fund this trial independently, which is seen as a positive surprise.
Market OpportunityWith ~1mn patients in the US, DME represents a significant opportunity for Eyepoint.
Bears Say
Investor ConcernsInitial press release lacked detail from the control arm, which likely left some investors concerned.
Transparency IssuesThere are expectations from Duravyu's 24-week diabetic macular edema update in the first quarter of 2025, which could impact investor sentiment until more information is revealed.
---
Ownership Overview
13.16% Insiders
19.18% Mutual Funds
0.23% Other Institutional Investors
57.46% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $5.90 and its highest was $29.31 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
EyePoint Pharmaceuticals Inc’s market cap is $446.36M.
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Feb 27, 2025 which is in 6 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.006.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -0.49.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 68,251,030 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went down -4.056%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in EYPT
---
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.60 (334.65% Upside)
$27.60 (334.65% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.14%
12-Months-Change
Fundamentals
Return on Equity
-74.68%
Trailing 12-Months
Asset Growth
88.02%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
EYPT Stock 12 Month Forecast
Average Price Target
$27.60
▲(334.65% Upside)
Technical Analysis
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
9/22 ratings generated profit
1 Year Average Return
+50.95%
reiterated a buy rating 3 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 40.91% of your transactions generating a profit, with an average return of +50.95% per trade.
---